跳到正文
原文
Endpoints News 生物医药· Ayisha Sharma·· 26 天前AI 评分46

Roche KRAS G12C 抑制剂头对头试验显示降低既往治疗 NSCLC 死亡风险 44%

#ESMO26: Roche details magnitude of its KRAS G12C inhibitor’s win over rivals in lung cancer trial

AI 导读

Roche 的新一代 KRAS G12C 抑制剂在既往接受过治疗的突变非小细胞肺癌头对头试验中,使死亡风险降低 44%。

正文

MADRID — Roche’s next-gen KRAS G12C in­hibitor cut the risk of death by 44% in pre­vi­ous­ly treat­ed mu­tant non-small cell lung can­cer in a head-to-head tri­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news